Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

Messoud Ashina*, Jan Hoffmann, Håkan Ashina, Debbie L. Hay, Yadira Flores-Montanez, Thien Phu Do, Roberto De Icco, David W. Dodick

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

Original languageEnglish
Pages (from-to)285-299
Number of pages15
JournalMayo clinic proceedings
Issue number2
Publication statusPublished - Feb 2024


Dive into the research topics of 'Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside'. Together they form a unique fingerprint.

Cite this